서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Publications

Detailed Information

Development of a (177)Lu-Labeled RGD Derivative for Targeting Angiogenesis

DC Field Value Language
dc.contributor.authorJu, Chang Hwan-
dc.contributor.authorJeong, Jae Min-
dc.contributor.authorLee, Yun-Sang-
dc.contributor.authorKim, Young Joo-
dc.contributor.authorLee, Dong Soo-
dc.contributor.authorLee, Myung Chul-
dc.contributor.authorJeong, Seo Young-
dc.contributor.authorChung, June-Key-
dc.contributor.authorLee, Byung Chul-
dc.date.accessioned2012-07-03T06:07:01Z-
dc.date.available2012-07-03T06:07:01Z-
dc.date.issued2010-12-
dc.identifier.citationCANCER BIOTHERAPY AND RADIOPHARMACEUTICALS; Vol.25 6; 687-691ko_KR
dc.identifier.issn1084-9785-
dc.identifier.urihttps://hdl.handle.net/10371/78266-
dc.description.abstractVarious Arg-Gly-Asp (RGD) derivatives have been labeled with various radioisotopes for targeting alpha(v)beta(3) integrin, which is expressed during angiogenesis in tumor. In this study, 2-(4`-isothiocyanatobenzyl)-1,4,7-triazacyclononane- 1,4,7-triacetic acid (NOTA-SCN) and its c(RGDyK) conjugate (NOTA-SCN-c(RGDyK)) were labeled with (177)Lu, which is a near ideal radionuclide for treating tumors because it emits therapeutic beta particles and gamma rays for monitoring. (177)Lu (250 MBq) was labeled with 50 mu g NOTA-SCN-c(RGDyK) quantitatively. The specific activity of (177)Lu-NOTA-SCN-c(RGDyK) was 1.44 X 10(5) Ci/mol. Biodistribution study was performed in Balb/c mice xenografted with CT-26 (mouse colon cancer) cells. The highest uptake was found in kidneys (7.56% +/- 0.71% ID/g at 1 hour), and tumor uptake was 1.70% +/- 0.33% ID/g at 1 hour postinjection. Moderate tumor-to-blood (2.36 +/- 0.29) and tumor-to-muscle (2.06 +/- 0.40) ratios were observed. This study shows that (177)Lu-NOTA-SCN-c(RGDyK) is a potential therapeutic agent for angiogenic tumors, but special care is required to prevent kidney toxicity.ko_KR
dc.description.sponsorshipThis work was supported by an NRF of Korea grant
(R0A-2008-000-20116-0) and the Converging Research Program
(2010K001055) funded by the Ministry of Education,
Science and Technology.		ko_KR
dc.language.isoenko_KR
dc.publisherMARY ANN LIEBERT INCko_KR
dc.subjectangiogenesisko_KR
dc.subjectLu-177ko_KR
dc.subjectRGDko_KR
dc.subjectradionuclide therapyko_KR
dc.subjectNOTAko_KR
dc.subjectlutetiumko_KR
dc.titleDevelopment of a (177)Lu-Labeled RGD Derivative for Targeting Angiogenesisko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor주창환-
dc.contributor.AlternativeAuthor정재민-
dc.contributor.AlternativeAuthor이윤상-
dc.contributor.AlternativeAuthor김영주-
dc.contributor.AlternativeAuthor이병철-
dc.contributor.AlternativeAuthor이동수-
dc.contributor.AlternativeAuthor정준기-
dc.contributor.AlternativeAuthor이명철-
dc.contributor.AlternativeAuthor정서영-
dc.identifier.doi10.1089/cbr.2010.0825-
dc.citation.journaltitleCANCER BIOTHERAPY AND RADIOPHARMACEUTICALS-
dc.description.citedreferenceJEONG JM, 2009, NUCL MED MOL IMAGING, V43, P330-
dc.description.citedreferenceMOON EH, 2009, NUCL MED MOL IMAGING, V43, P436-
dc.description.citedreferenceKIM KH, 2009, NUCL MED MOL IMAGING, V43, P582-
dc.description.citedreferenceChakraborty S, 2008, APPL RADIAT ISOTOPES, V66, P1196, DOI 10.1016/j.apradiso.2008.02.061-
dc.description.citedreferenceYoshimoto M, 2008, INT J CANCER, V123, P709, DOI 10.1002/ijc.23575-
dc.description.citedreferenceChakraborty S, 2008, NUCL MED BIOL, V35, P589, DOI 10.1016/j.nucmedbio.2008.03.003-
dc.description.citedreferenceJeong JM, 2008, J NUCL MED, V49, P830, DOI 10.2967/jnumed.107.047423-
dc.description.citedreferenceJeong JM, 2008, SEMIN NUCL MED, V38, pS19, DOI 10.1053/j.semnuclmed.2007.10.003-
dc.description.citedreferenceChakravarty R, 2008, NUCL MED BIOL, V35, P245, DOI 10.1016/j.nucmedbio.2007.10.009-
dc.description.citedreferenceJia B, 2006, BIOCONJUGATE CHEM, V17, P1069, DOI 10.1021/bc060055b-
dc.description.citedreferenceHaubner R, 2006, EUR J NUCL MED MOL I, V33, pS54, DOI 10.1007/s00259-006-0136-0-
dc.description.citedreferenceZhang XZ, 2006, J NUCL MED, V47, P113-
dc.description.citedreferenceMeyer A, 2006, CURR PHARM DESIGN, V12, P2723-
dc.description.citedreferenceJeong JM, 2003, CANCER BIOTHER RADIO, V18, P707-
dc.description.citedreferencePillai MRA, 2003, APPL RADIAT ISOTOPES, V59, P109, DOI 10.1016/S0969-8043(03)00158-1-
dc.description.citedreferenceJanssen M, 2002, CANCER BIOTHER RADIO, V17, P641-
dc.description.citedreferenceJanssen ML, 2002, CANCER RES, V62, P6146-
dc.description.citedreferenceCarmeliet P, 2000, NATURE, V407, P249-
dc.description.citedreferencePlow EF, 2000, J BIOL CHEM, V275, P21785-
dc.description.citedreferenceAllman R, 2000, EUR J CANCER, V36, P410-
dc.description.citedreferenceHaubner R, 1999, J NUCL MED, V40, P1061-
dc.description.citedreferenceBROOKS PC, 1995, J CLIN INVEST, V96, P1815-
dc.description.citedreferenceBROOKS PC, 1994, SCIENCE, V264, P569-
dc.description.citedreferenceMCMURRY TJ, 1993, BIOCONJUGATE CHEM, V4, P236-
dc.description.citedreferenceSTUDER M, 1992, BIOCONJUGATE CHEM, V3, P337-
dc.description.citedreferenceRUOSLAHTI E, 1987, SCIENCE, V238, P491-
dc.description.citedreferenceCACHERIS WP, 1987, INORG CHEM, V26, P958-
dc.description.tc0-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

Show Simple Item Record
Find it @ SNU

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share

qrcode
SNS Share